Hugo Hämmerle
Chief Executive Officer at NMI Technologietransfer GmbH
Profile
Hugo Hämmerle is the founder of Tissue Engineering Technologies AG, which was founded in 2000.
He held the position of Member-Supervisory Board from 2000 to 2010.
Dr. Hämmerle currently holds the position of Deputy Chairman-Supervisory Board at Retina Implant AG.
He is also the Director-Natural & Medical Science Institute at Eberhard Karls Universität Tübingen since 2012.
Additionally, he is the Managing Director at NMI Technologietransfer GmbH.
Dr. Hämmerle previously worked at STRATEC SE from 1990 to 2014, where he held the position of Member-Supervisory Board in 2014.
In terms of education, Dr. Hämmerle obtained a doctorate degree from Eberhard Karls Universität Tübingen in 1987.
He also holds an undergraduate degree from the University of Hohenheim, which was conferred in 1982.
Hugo Hämmerle active positions
| Companies | Position | Start |
|---|---|---|
Retina Implant AG
 Retina Implant AG Medical SpecialtiesHealth Technology Retina Implant AG develops sub retinal implants for partially sighted and blind patients. The company was founded in 2003 and is headquartered in Reutlingen, Germany. | Director/Board Member | - |
| Eberhard Karls Universität Tübingen | Corporate Officer/Principal | - |
NMI Technologietransfer GmbH
 NMI Technologietransfer GmbH Miscellaneous Commercial ServicesCommercial Services Part of NMI Naturwissenschaftliches & Medizinisches Institut, NMI Technologietransfer GmbH is a contract research organization that consists of three business units: NMI TT Pharmaservices, NMI TT Testing Services, and NMI TT Microdevices. The company is based in Reutlingen, Germany. NMI TT Pharmaservices offers advanced cell-based assays, novel and better cell models, and custom cell lines for the pharma industry, oncology, academia, and cancer research. Additionally, the German company offers electrophysiology services on different target systems such as heart, brain, and retina. The CEO of the company is Hugo Hämmerle. | Chief Executive Officer | - |
Former positions of Hugo Hämmerle
| Companies | Position | End |
|---|---|---|
| STRATEC SE | Director/Board Member | 2014-06-17 |
Tissue Engineering Technologies AG
 Tissue Engineering Technologies AG BiotechnologyHealth Technology Part of Lonza Group AG, Tissue Engineering Technologies AG is a German company that manufactures bacterial and virus vaccines, toxoids, and analogous products. The company is based in Reutlingen City, Germany. The company was founded in 2000 by Hugo Hämmerle. The CEO is Detlef Schumann. | Founder | - |
Training of Hugo Hämmerle
| University of Hohenheim | Undergraduate Degree |
| Eberhard Karls Universität Tübingen | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| STRATEC SE | Health Technology |
| Private companies | 3 |
|---|---|
Tissue Engineering Technologies AG
Tissue Engineering Technologies AG BiotechnologyHealth Technology Part of Lonza Group AG, Tissue Engineering Technologies AG is a German company that manufactures bacterial and virus vaccines, toxoids, and analogous products. The company is based in Reutlingen City, Germany. The company was founded in 2000 by Hugo Hämmerle. The CEO is Detlef Schumann. | Health Technology |
Retina Implant AG
Retina Implant AG Medical SpecialtiesHealth Technology Retina Implant AG develops sub retinal implants for partially sighted and blind patients. The company was founded in 2003 and is headquartered in Reutlingen, Germany. | Health Technology |
NMI Technologietransfer GmbH
NMI Technologietransfer GmbH Miscellaneous Commercial ServicesCommercial Services Part of NMI Naturwissenschaftliches & Medizinisches Institut, NMI Technologietransfer GmbH is a contract research organization that consists of three business units: NMI TT Pharmaservices, NMI TT Testing Services, and NMI TT Microdevices. The company is based in Reutlingen, Germany. NMI TT Pharmaservices offers advanced cell-based assays, novel and better cell models, and custom cell lines for the pharma industry, oncology, academia, and cancer research. Additionally, the German company offers electrophysiology services on different target systems such as heart, brain, and retina. The CEO of the company is Hugo Hämmerle. | Commercial Services |
- Stock Market
- Insiders
- Hugo Hämmerle
